C Cure 709Alternative Names: C-709; C-Cure 709; Genetically modified cytotoxic T lymphocyte - CellCure
Latest Information Update: 16 Jul 2016
At a glance
- Originator CellCure A/S
- Class Antineoplastics
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Malignant melanoma
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Malignant-melanoma in Denmark (Intratumoural, Injection)
- 15 Feb 2006 Final results from a phase I clinical trial in patients with metastatic Melanoma have been added to the adverse events and Cancer therapeutic trials sections